Standout Papers

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor... 2019 2026 2021 2023 334
  1. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway (2019)
    Yu Kato, Kimiyo Tabata et al. PLoS ONE

Immediate Impact

6 by Nobel laureates 26 from Science/Nature 63 standout
Sub-graph 1 of 23

Citing Papers

Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
2023 Standout

Works of Yasuhiro Funahashi being referenced

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
2019 Standout
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Yasuhiro Funahashi 2395 2099 918 1011 116 5.9k
Anderson J. Ryan 3812 2893 1459 1318 156 7.3k
Scott M. Wilhelm 3420 2785 1286 1616 69 8.8k
Guido Bocci 2357 2527 1211 990 203 5.7k
Alexander Laird 2646 1650 743 1197 95 4.8k
Eliot M. Rosen 4589 1738 1240 979 143 7.8k
Stephen R. Wedge 3588 2549 1415 1563 101 6.9k
T.R. Jeffry Evans 1814 1912 794 674 106 4.3k
M. E. Scheulen 2258 2572 729 1146 178 5.5k
Miguel A. Villalona‐Calero 2662 3095 1054 2029 184 6.2k
Ronald D. Finn 1770 1810 764 1849 174 8.0k

All Works

Loading papers...

Rankless by CCL
2026